Infectious Disease Point-of-care (POC) Diagnostics Market

Infectious Disease Point-of-care (POC) Diagnostics Market

Growth Factors of Infectious Disease Point-of-care (POC) Diagnostics Market

The Infectious Disease Point-of-care (POC) Diagnostics market size was valued at USD 15.81 billion in 2023, and the market is now projected to grow from USD 15.21 billion in 2024 to USD 12.46 billion by 2032, exhibiting a CAGR of -2.8% during the forecast period of 2024-2032.

In the havoc of the widespread the Infectious disease point-of-care diagnostics market growth was largely influenced globally as the pharmaceutical companies and institutes for research had a deep focus on the patients attacked by the coronavirus and their diagnosis and treatments. The presentation of progressed items and speedy turnaround time units boosted the advertise development within the estimate timeframe.

In spite of the colossal endeavors put into overseeing irresistible infections, the improvement of low-cost, exact, and touchy POC items is in enormous request. Nanotechnology has opened the entryways for far reaching applications within the healthcare industry. Researchers over the globe have emphasized the presentation of nanoparticle-based and nano-device-based POC stages and tests.

With reference to the advantages such as speedy turnaround time and the capacity to form quick treatment choices, POC conclusion has gotten to be a pivotal portion of patient-centric healthcare. There has been a particular move from centralized to decentralized point-of-care testing for irresistible illnesses, progressing patient care. The developing request for fast tests has energized the showcase players to supply POC items to decentralized areas, subsequently driving this marketplace.

Comprehensive Analysis of Infectious Disease Point-of-care (POC) Diagnostics Market

On the technique basis, the market structure is sub parted as atomic diagnostics, horizontal stream immunoassay, agglutination test and the Immuno-concentration/ flow through measure. On the bifurcation of the disease segment basis, the market arena is portioned into tuberculosis, hepatitis B infection, influenza, HIV, clostridium difficile infections (CDI), pneumonia/streptococcus-associated contaminations, hepatitis C infection, respiratory syncytial infection, MRSA and others. The worldwide frequency rate of irresistible illnesses and rising beneath conclusion burden has brought about within the quick appropriation of POC testing packs. The market arena on the division of end-user basis is further fragmented as nursing homes, critical care & retail clinics, healing center bedside, physician's office labs, domestic & self-testing and others.

The territorial area of North America is stated to made a leading impact on the worldwide infectious disease point-of-care (POC) diagnostics market share with a globally impressive valuation of USD 5.68 billion in the projected timeframe. The leading attribute of this territory is inferable to the expanding appropriation of progressed point-of-care diagnostics for the location of different irresistible illnesses.

The market for infectious disease point-of-care diagnostics is semi-consolidated owing to the solid item portfolios and surprising dispersion arrange of major companies in created and rising nations. The operating players such as F. Hoffmann-La Roche AG (Switzerland), Cepheid Inc. (U.S.), BD (U.S.), Thermofisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Quidel Corporatio (U.S.), Trinity Biotech (Ireland), Cardinal Health Inc. (U.S.), and Abbott (U.S.) Research facilities lead the advertise, accounting for a major market impression over the globe.

In between the month of February 2022, the Trinity Biotech company received endorsement for its TrinScreen HIV, an HIV screening item, from the World Health Organization (WHO). It may be a fast test giving comes about in less than 12 minutes from a finger adhere drop of blood.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Unit Value (USD Billion)

Growth Rate CAGR of -2.8% from 2023-2030

Segmentation By Technique

Lateral Flow Immunoassay (LFIA)

Agglutination Test

Flow-through test/Immunoconcentration Assay

Molecular Diagnostics

Others

By Disease

HIV

Hepatitis B Virus

Pneumonia/Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV)

Influenza

Clostridium Difficile Infections (CDI)

Hepatitis C Virus

Methicillin-Resistant Staphylococcus Aureus (MRSA)

Tuberculosis (TB)

COVID-19

Others

By End-User

Hospital Bedside

Physician's Office Lab

Urgent Care & Retail Clinics

Home & Self-testing

Nursing Home

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)